NCT04905121View on ClinicalTrials.gov

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

April 22, 2022

Study Completion Date

April 22, 2022

Conditions
Short Lasting Unilateral Neuralgiform Headache Attacks
Interventions
DRUG

Psilocybin

Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses

Trial Locations (1)

Unknown

King's College London, London

Sponsors
All Listed Sponsors
lead

Beckley Psytech Limited

INDUSTRY

NCT04905121 - Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) | Biotech Hunter | Biotech Hunter